System and method for processing, incubating, and/or selecting biological cells

Patent metadata

Field	Value
Publication number	US-10251990-B2
Application number	US-201715498881-A
Country	US
Kind code	B2
Filing date	Apr 27, 2017
Priority date	Apr 29, 2016
Publication date	Apr 9, 2019
Grant date	Apr 9, 2019

Abstract

A method for automated processing of a cellular product comprising target substrate cells, the method comprising providing a separation apparatus configured to associate with a disposable sterile circuit comprising a separator in communication with the cellular product. The apparatus and disposable sterile circuit are configured to remove platelets from the cellular product to form a platelet-depleted cellular product, resuspend the platelet-depleted cellular product in media to form a resuspended platelet-depleted cellular product, receive an agent having an association with the target substrate cells of the resuspended platelet-depleted cellular product, incubate the agent with the target substrate cells over a period sufficient for the agent to bind with and/or enter the target substrate cells to form a first mixture comprising agent-target substrate cell complexes, unbound/unassociated agent, and non-target substrate cells, and remove unbound/unassociated agent to form a second mixture comprising the agent-target substrate cell complexes and non-target substrate cells.

First claim

The invention claimed is:

1. A system for automated processing of a cell product comprising surface antigen expressing cells, in preparation for surface antigen expressing cell selection, the system comprising:
a reusable separation apparatus controlled by a microprocessing controller unit driven by software, wherein the apparatus and microprocessing controller unit are configurable with a plurality of settings;
a disposable sterile circuit configured to associate with the reusable separation apparatus, the disposable sterile circuit comprising a spinning membrane separator comprising a porous membrane, wherein the separator comprises an inlet and first and second outlets;
a cell product in communication with the inlet of the separator, wherein the separation apparatus is configured in a first cycle by the microprocessing controller unit to flow the cell product into the inlet of the separator, separate platelets and supernatant from the first outlet into a filtrate container, and separate remaining cellular components from the second outlet into an in-process container;
wash media within a media container in communication with the in-process container, wherein the separator is configured by the separation apparatus in a second cycle to flow the wash media into the in-process container containing the remaining cellular components to form resuspended platelet-depleted cell product;
an external injection port located on the in-process container configured to receive an agent having an association with the surface antigen expressing cells of the resuspended platelet-depleted cell product, wherein the in-process container is configured to incubate the agent with the surface antigen expressing cells over an incubation period sufficient for the agent to bind and/or associate with the surface antigen expressing cells to form a first mixture, comprising antigen-agent complexes, unbound/unassociated agent, and cells not presenting the antigen;
wherein the separation apparatus is configured in a third cycle to separate the first mixture into unbound/unassociated agent, directed from the first outlet into the filtrate container, and a second mixture, comprising antigen-agent complexes and cells not expressing the antigen, directed from the second outlet to a retentate container, wherein the second mixture is ready for target cell selection.

2. The system of claim 1 , wherein the plurality of settings further comprises:
a spinner inlet flow rate of 80 mL/min, a reduction spinner revolution rate of 4000 rpm, a desired spinner inlet packed cell volume (PCV)of 6%, and a reduction retentate pump rate of 8 mL/min for the first cycle and the second cycle; and
a spinner inlet flow rate of 148 mL/min, a reduction spinner revolution rate of 2750 rpm, a desired spinner inlet packed cell volume (PCV)of 7%, and reduction retentate pump rate of 16 mL/min for the third cycle.

3. The system of claim 1 , wherein the wash media comprises at least one of Phosphate-Buffered Saline (PBS), Ethylenediaminetetraacetic Acid (EDTA), Human Serum Albumin (HAS), and saline.

4. The system of claim 1 , wherein the porous membrane comprises pore sizes greater than the size of platelets and the unbound/unassociated agent but less than the size of the cellular components.

5. The system of claim 4 , wherein the pore sizes are within the range of 4.0 μm to 10.0 μm.

6. The system of claim 1 , wherein the reusable separation apparatus controlled by a microprocessing controller unit is configured to automatically pause between the first cycle and the second cycle, and/or a beginning of the incubation period and the third cycle, to allow an operator may manually mix the in-process container.

7. The system of claim 1 , wherein the incubation period further comprises an automated incubation cycle, wherein the separation apparatus controlled by the microprocessing controller unit is configured to cycle the agent and the resuspended platelet-depleted cell product from the in-process container through the separator and back to the in-process container in a cyclical pathway.

8. The system of claim 1 , wherein during the incubation period, the separation apparatus controlled by the microprocessing controller unit is configured to add additional volume of fluid and/or substrate gradually and/or intermittently, via a second media container in communication with the in-process container, to the resuspended platelet-depleted cell product.

9. The system of claim 1 , wherein the in-process container is configured to receive the agent within an enclosed, ventilated laboratory workspace, wherein the agent is incubated on a shaker with the surface antigen expressing cells over the incubation period to form the first mixture.

10. The system of claim 1 , wherein the plurality of settings comprises:
a spinner inlet flow rate of 150 mL/min, a reduction spinner revolution rate of 3750 rpm, a desired spinner inlet packed cell volume (PCV) of 3%, and a reduction retentate pump rate of 15 mL/min for the first, second, and third cycles; or
a spinner inlet flow rate of 80 mL/min, a reduction spinner revolution rate of 4000 rpm, a desired spinner inlet packed cell volume (PCV)of 6%, and reduction retentate pump rate of 8 mL/min for the first, second, and third cycles.

Assignees

• Fenwal Inc

Inventors

• Wegener Christopher J
• Olson Bret M
• Schlinker Alaina
• Binninger Steven
• Kadakia Avnie A

Classifications

• G01N35/1016

  Control of the volume dispensed or introduced · CPC title

• A61M1/362

  changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity · CPC title

• C12M27/02

  Stirrer or mobile mixing elements · CPC title

• C12M29/04

  Filters; Permeable or porous membranes or plates, e.g. dialysis · CPC title

• C12M29/00

  Means for introduction, extraction or recirculation of materials, e.g. pumps (pumps per se F04B) · CPC title